Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

For Humphry Leue, the Cancer Screening Project he helped launch last week is meaningful on a very personal level. “I myself ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Hong Kong has seen a 30 per cent increase in new cervical cancer cases over the past decade, reversing a downtrend since the ...

Saskatchewan cervical cancer patients now have access to a specialized radiation therapy treatment previously only available ...

Around 11,500 Americans are diagnosed with cervical cancer each year, according to data from the Centers for Disease Control ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Gynecologic oncologist Dr. John Wallbillich says people often don't have symptoms of cervical cancer, so it's important to ...

Every minute, 38 people are diagnosed with cancer, and 18 people die from it globally, according to the World Health ...